Dorzagliatin is an innovative treatment for type 2 diabetes. This
is the first drug from the group of glucokinase activators that can
simultaneously affect two key metabolic links: pancreatic beta cells
and liver.
The drug is aimed at restoring the natural mechanism of regulation
of glucose levels. It doesn’t just lower blood sugar, but helps the organs involved in
controlling it to start working properly. In the pancreas, it increases
the sensitivity of beta cells to glucose, stimulating the timely release of insulin.
In the liver, it reduces glucose production and increases its utilization.
Mechanism of action of Dorzagliatin
Beta-cell support
One of the main problems in T2DM is a decrease in the sensitivity of beta-cells to
glucose and delayed insulin secretion. Normally, an increase in blood sugar
after a meal triggers a rapid and powerful insulin response.
In diabetic patients, this phase is disrupted.
Dorzagliatine activates glucokinase in beta cells, which allows cells to respond more quickly and
accurately to glucose growth. This helps restore the first phase
of insulin secretion and improve the subsequent phase if a long
-term reduction in sugar levels is required.
Thus, the drug helps to ‘turn on’ the insulin response at the right time,
which is especially important in the first hours after eating — when the most
pronounced glycemic spikes occur.
Reduction of excess glucose production in the liver
The liver in type 2 diabetes often behaves like an ‘independent laboratory’:
synthesizes glucose, even when it is already elevated in the blood. This is due to the loss
of normal insulin sensitivity and impaired glucokinase function.
Dorzagliatin activates hepatic glucokinase, thereby reducing the rate
of gluconeogenesis and increasing the conversion of glucose to glycogen. This results in more
stable blood glucose readings between meals and at night.
The patient receives predictable sugar values without ‘morning peaks’, and the doctor-
stable control due to exposure to the main cause of increased
fasting glucose.
Clinical significance of Dorzagliatin
The drug doesn’t just reduce glucose — it affects key mechanisms
of the disease. This makes it particularly valuable in the complex therapy of T2DM, especially
in patients with:
- with severe fasting hyperglycemia -often due to excessive production of glucose in the liver;
- with a violation of the first phase of insulin secretion — one of the first targets in T2DM;
- with unstable glycemic indicators during the day — with a high risk of complications.
The use of Dorzagliatin allows not only to control the average
sugar level, but also to reduce its variability. Namely, fluctuations in glucose, and not
just its absolute values, are now considered a key factor in the development
of complications in T2DM.
In clinical trials, Dorzagliatin demonstrated:
- Reduced levels of glycated hemoglobin (HbA1c) are an important marker of long-term control;
- reduced fasting and post-meal glucose -reflects effectiveness in both critical periods;
- improvement of beta-cell function indicators (e.g., HOMA2-beta) – indicates a positive effect on the cause of the disease itself;
- stabilization of the daily glycemic profile — reduction of sugar spikes throughout the day.
Benefits of the drug for the treatment of diabetes
The complex mechanism of action makes Dorzagliatin a promising option
both for starting therapy and for enhancing the effect with insufficient control against the
background of other drugs.
Key benefits:
- Dual action: simultaneously on the pancreas and liver-allows you to act on both main mechanisms of hyperglycemia;
- Restoration of the physiological response: the drug does not’ put pressure ‘ on the metabolism, but helps the body to respond to glucose as intended by nature;
- The oral form is convenient for most patients, especially the elderly;
- Minimal risk of hypoglycemia — relevant when used in monotherapy or in combination with drugs that do not cause a drop in sugar;
- Flexibility in combination therapy — can be added to an already prescribed treatment without the risk of cross-effects.
For the patient, this means fewer injections and sugar fluctuations, and for the doctor
, it is an effective control tool without significant side effects.
Practical application of Dorzagliatin
For patients
If your fasting sugar level remains elevated despite taking other
medications, Dorzagliatin may be just the right drug to give
your body a’ second chance ‘ at stability. It helps the liver to stop
uncontrolled release of glucose into the blood at night and in the early morning-precisely at those
hours when the patient most often faces unpleasant symptoms: dry
mouth, headache, feeling broken.
The effect is especially noticeable after eating. If earlier in 30-60 minutes after
a meal there was weakness, dizziness or irritability-these were
the consequences of glucose spikes. Dorsagliatine helps the pancreas
respond to food faster and ‘ cut ‘ the peak glucose before it begins to affect
the blood vessels and nervous system.
In addition, the drug can be useful for those who feel that other drugs
are no longer ‘pulling’: sugar is then reduced, then rises again for no obvious reason. This is a sign
of depletion of beta-cell function. Dorsagliatine supports these cells by enhancing
their response to glucose.
It’s not just sugar control. This is an improvement in the quality of life: the patient regains
a sense of energy, clarity and stability, which is so lacking in
unstable glycemia.
For doctors
- Patients with inadequate postprandial control, despite basic therapy — are candidates for Dorzagliatin supplementation.
- If the function of beta-cells is impaired and there is no response to stimulants, it is possible to restore insulin secretion.
- It can be used as a starting therapy, especially if the diagnosis is made against the background of already pronounced hyperglycemia on an empty stomach and after eating.
- Assessment via HOMA2, insulin response to exercise, and glycemic profile will give an objective idea of effectiveness.
- Combined with metformin, DPP-4 inhibitors, and even insulin , it expands therapeutic options without conflict in the mechanism of action.
Dorzagliatin is a modern drug that focuses not just on reducing
glucose, but on restoring the mechanisms of its regulation. . It helps
the pancreas and liver to work in concert, as it should
normally.
This approach is especially valuable in the progressive course of T2DM, when
several links in the regulation of carbohydrate metabolism are disrupted at once. The efficacy and
safety of Dorzagliatin have been confirmed by clinical studies, and
the physiological nature of its mechanism of action makes it a logical choice in the selection
of modern therapy.
Sources:
https://pubmed.ncbi.nlm.nih.gov
https://www.huamedicine.com
https://onlinelibrary.wiley.com
https://synapse.patsnap.com
